Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

164.84 0.76 −0.46%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
−139×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
253.15 0.00 0.00 160.21 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
7 5 4 2 2 5 1 3 4 3
P/S ratio
9.71 5.85 10.94 8.59 14.89 7.02 7.36 11.86 20.63 12.73
Altman Z-Score
39.51 19.33 36.08 8.48 5.83 2.85 2.44 4.23 22.21 15.20
P/FCF ratio
184.10 47.07 232.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
7.79 6.23 6.49 5.35 2.98 2.63 1.55 0.26 3.06 0.74
Beneish M-Score
(2.05) (3.28) (2.64) 2.81 (3.28) (2.90) (2.73) (2.79) (2.26) (2.96)
P/Operating CF
338.72 74.71 115.82 (485.50) 315.81 (443.57) (503.35) (350.04) 15,601.75 943.64
P/B ratio
9.47 6.74 11.41 3.02 5.02 3.51 3.93 8.08 10.31 9.84
Price to Tangible BV
10.03 6.89 11.44 9.06 13.75 10.96 13.35 33.13 18.09 14.43
EV/Sales
8.90 5.12 10.19 8.11 14.21 7.76 8.35 12.93 20.71 12.86
EV/EBITDA
111.01 253.28 0.00 0.00 0.00 577.48 0.00 0.00 0.00 0.00
EV/Operating CF
82.73 31.27 97.92 (5,206.45) (139.01) 92.32 (71.40) (70.47) (129.49) (441.27)
EV/FCF
168.84 41.25 216.06 (377.22) (106.79) (98.86) (37.38) (52.18) (117.49) (167.07)
Quick Ratio
6.50 5.06 5.24 3.68 8.86 7.06 5.37 4.53 5.05 3.82
Current Ratio
7.09 5.58 5.81 4.56 9.45 7.67 6.13 5.34 5.99 4.69
Net Debt/EBITDA
(10.45) (36.95) 19.98 3.14 2.67 (15.53) (0.02) (0.64) 2.91 1.31
Debt/Assets
0.00% 0.00% 0.00% 7.14% 24.87% 33.60% 35.27% 37.57% 7.13% 7.62%
Debt/Equity
0.00 0.00 0.00 0.09 0.37 0.60 0.67 0.77 0.09 0.10
Asset Turnover
0.91 1.06 0.97 0.46 0.25 0.29 0.28 0.32 0.40 0.54
Operating CF/Net income
2.72 (283.60) (1.46) (0.02) 0.19 (0.50) 0.33 0.43 0.42 0.08
Capex/Depreciation
(1.27) (1.15) (1.73) (0.35) (0.11) (1.30) (0.79) (0.54) (0.17) (0.62)
Interest Coverage
4.77 (1.66) (5.77) (19.61) (8.75) (2.46) (6.00) (9.44) (12.19) (43.06)
ROE
4.26% (0.07%) (8.30%) 3.64% (17.95%) (7.91%) (17.76%) (27.16%) (23.83%) (26.38%)
ROA
3.60% (0.06%) (6.95%) 3.01% (13.20%) (4.83%) (9.67%) (13.86%) (15.29%) (20.09%)
ROIC
12.37% (7.43%) (24.35%) (5.64%) (15.05%) (3.91%) (9.69%) (15.48%) (14.78%) (28.00%)
Return on Tangible Assets
4.09% (0.07%) (7.83%) 6.79% (27.12%) (10.09%) (21.29%) (31.71%) (30.98%) (38.54%)
Average Days of Receivables
45.64 38.17 37.60 59.17 58.51 41.51 46.55 46.22 57.82 78.12
Research and Development Expense of Revenue
25.55% 24.43% 27.40% 28.82% 37.96% 34.35% 47.12% 45.68% 39.29% 29.68%
Selling, General and Administrative Expense of Revenue
56.61% 60.44% 65.94% 74.53% 76.19% 60.97% 68.20% 71.20% 68.10% 65.38%
Intangible Assets out of Total Assets
0.05 0.02 0.00 0.55 0.42 0.38 0.37 0.37 0.34 0.23
Share Based Compensation of Revenue
7.68% 11.05% 14.18% 15.36% 20.66% 10.25% 13.63% 13.83% 13.09% 12.46%
Graham Net Nets
0.09 0.13 0.07 0.06 0.04 0.01 (0.01) (0.02) 0.03 0.04
Graham Number
3.27 0.00 0.00 11.74 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
0.40% 0.00% (0.66%) 0.62% (3.63%) (2.43%) (4.76%) (3.61%) (1.91%) (2.89%)
Free Cash Flow Yield
0.54% 2.12% 0.43% (0.25%) (0.89%) (1.12%) (3.04%) (2.09%) (0.85%) (0.60%)
Revenue per Share
3.47 4.63 5.13 6.34 5.06 6.33 5.96 6.50 7.27 8.87
Operating CF per Share
0.37 0.76 0.53 (0.01) (0.52) 0.53 (0.70) (1.19) (1.16) (0.26)
Capex per Share
(0.19) (0.18) (0.29) (0.13) (0.16) (1.03) (0.63) (0.42) (0.12) (0.42)
Free Cash Flow per Share
0.18 0.58 0.24 (0.14) (0.67) (0.50) (1.33) (1.61) (1.28) (0.68)
Cash per Share
2.91 3.46 3.98 4.66 9.09 8.92 7.43 6.10 6.05 4.87
Shareholders Equity per Share
3.56 4.02 4.92 18.02 15.00 12.65 11.17 9.53 14.54 11.47
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.56 4.02 4.92 18.02 15.00 12.65 11.17 9.53 14.54 11.47
Free Cash Flow
6.03 19.78 8.55 (5.09) (29.92) (23.07) (63.20) (78.01) (67.58) (39.06)
Working Capital
103.09 122.67 146.20 205.18 419.74 422.77 371.50 321.45 374.67 373.71
Capital Expenditures
(6.28) (6.31) (10.31) (4.72) (6.93) (47.78) (30.11) (20.25) (6.26) (24.27)
Net Current Asset Value
102.93 121.83 143.46 117.75 131.39 23.58 (28.52) (83.19) 241.97 237.65
EV/EBIT
240.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.05 0.04 0.06 0.02 0.03 0.16 0.11 0.06 0.02 0.05
Price to Operating Income
261.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.65 0.47 0.31 0.61 2.74 0.53 0.40 0.36 0.37 0.35
Cash ROIC
2.83% 7.69% 2.72% (0.56%) (2.26%) (1.70%) (5.11%) (7.02%) (5.85%) (3.89%)
Accounts Receivable Turnover
10.47 10.29 10.26 8.30 6.04 8.46 8.14 8.29 7.62 5.99
Accounts Payable Turnover
4.91 4.57 4.00 6.40 18.07 11.39 6.35 5.43 7.11 5.94
Inventory Turnover
2.96 2.33 2.05 1.38 3.14 3.43 2.27 1.89 1.89 1.84
Average Days of Payables
66.94 108.27 91.50 54.68 17.39 40.17 76.21 64.91 50.57 80.38
Days of Inventory on Hand
154.42 194.59 193.34 402.74 62.91 126.06 200.23 202.78 223.90 207.50
Average Receivables
10.93 15.48 17.66 28.55 37.24 34.75 34.76 37.96 50.30 84.68
Average Payables
3.30 4.61 6.27 6.03 5.08 5.85 10.87 13.92 13.23 18.83
Average Inventory
5.47 9.03 12.25 27.93 29.19 19.41 30.43 39.91 49.83 60.62
Average Assets
125.52 150.10 186.40 512.69 911.95 1,027.60 1,026.04 971.40 957.59 934.12
Average Common Equity
106.23 127.74 156.03 423.57 670.36 627.30 558.58 495.89 614.35 711.54

Fold the line items

Columns are period end dates